



Lesotho COVID-19 Emergency Preparedness and Response Project (P173939)

AFRICA EAST | Lesotho | Health, Nutrition & Population Global Practice |
IBRD/IDA | Investment Project Financing | FY 2020 | Seq No: 4 | ARCHIVED on 31-Jan-2022 | ISR47909 |

Implementing Agencies: Kingdom of Lesotho, Ministry of Health

Key Dates**Key Project Dates**

Bank Approval Date: 09-May-2020

Effectiveness Date: 27-May-2020

Planned Mid Term Review Date: --

Actual Mid-Term Review Date:

Original Closing Date: 30-Jun-2022

Revised Closing Date: 30-Jun-2024

Project Development Objectives

Project Development Objective (from Project Appraisal Document)

To prevent, detect and respond to the threat posed by COVID-19 to the Kingdom of Lesotho.

Has the Project Development Objective been changed since Board Approval of the Project Objective?

No

Components Table

Name

Component 1: Emergency COVID-19 Response:(Cost \$29675000.00 M)

Component 2: Project Implementation and Monitoring & Evaluation:(Cost \$3325000.00 M)

Overall Ratings

Name	Previous Rating	Current Rating
Progress towards achievement of PDO	<input type="checkbox"/> Satisfactory	<input type="checkbox"/> Satisfactory
Overall Implementation Progress (IP)	<input type="checkbox"/> Satisfactory	<input type="checkbox"/> Satisfactory
Overall Risk Rating	<input type="checkbox"/> High	<input type="checkbox"/> High

Implementation Status and Key Decisions

The Lesotho COVID-19 Emergency Preparedness and Response Project aim to support the Government of Lesotho's (GOL) effort to prevent, detect and respond to the threat posed by COVID-19. The project is aligned to the GOL's COVID-19 National Integrated Response Plan and complements support from other development partners. The project became effective on May 27, 2020. An Additional Financing for vaccine procurement and deployment as well as for activities to continue to support the COVID-19 response was approved on June 1, 2021. Implementation is proceeding as planned. The project has disbursed US\$12.78 million to date. Among others, the project has supported the procurement and deployment of COVID-19 vaccines as well as the procurement of critical equipment and medical supplies such as personal protective equipment for hospitals and health care workers, supported additional human resources and training, both for specialized and for community health workers, and supported the refurbishment of the Mafeteng COVID-19 treatment center, which provides critical medical care for COVID-19 patients in the district of Mafeteng and the country.



MPA Program Development Objective

The Program Development Objective is to prevent, detect and respond to the threat posed by COVID-19 and strengthen national systems for public health preparedness

Multiphase Programmatic Approach (MPA) Status

The Additional Financing (MPA AF-V) to the COVID-19 Strategic Preparedness and Response Program utilizing the Multiphase Programmatic Approach (“Global COVID-19 MPA”) was approved by the Board on October 13, 2021. The AF-V is significantly expanding Bank support to client countries for COVID-19 vaccination, with the aim to support vaccination of 1 billion people globally. The AF-V was approved with an envelope of US\$12 billion (\$6 billion from IDA and \$6 billion from IBRD) in financing. This financing is critical to expanding affordable and equitable financing for vaccine purchase and deployment. The AF-V is expected to enable vaccination for up to 750 million people, with potential surge capacity for an additional 250 million people in the poorest countries (depending on the delivered price of approved vaccines) while scaling support to strengthen immunization delivery, with design flexibility at the country level. The AF-V is a scale-up of planned vaccination activities anticipated and supported under the Global COVID-19 MPA and a key contribution to the WBG’s overall COVID-19 response.

As of January 17, 2022, the Bank has approved 83 operations to support vaccine procurement and rollout in 69 countries amounting to \$7.6 billion. The 83 AF-V operations approved, include 6 operations that involved restructuring of parent projects (Bhutan, Cameroon, North Macedonia, Philippines, and Pakistan) and in the case of Lebanon, restructuring of the Health Resilience Project. Of the 83 approved operations: (i) 45 are in Africa – 21 in AFE and 24 in AFW; (ii) 8 in East Asia; (iii) 9 in Europe and Central Asia; (iv) 6 in Latin America and the Caribbean; (v) 7 in the Middle East and North Africa; and (vi) 8 in South Asia. Forty-three (43) projects are disbursing. Thirty new operations are under various stages of processing. Total disbursements as of January 17, 2022, under these projects, amount to US\$1.8 billion or 24% of overall commitments. As with the MPA operations, streamlined procedures, delegated approval, coupled with flexible project design and intensified efforts across the Bank have contributed to the rapid design and processing of the operations. Seventy (70) loan/financing agreements have been signed. Also, sixty (60) loan/financing agreements have become effective; several others are expected to become effective in the coming weeks. Implementation of the AF-V operations, as with MPA operations is facing challenges as several countries are still under different levels of lockdown or mobility restrictions and counterparts and Bank teams are operating from home. Countries are dealing with new waves of infections as the Omicron variant is spreading rapidly among populations. The variant, which was first identified in South Africa and Botswana, has been detected in more than 80 nations by mid-December 2021.

Risks

Systematic Operations Risk-rating Tool

Risk Category	Rating at Approval	Previous Rating	Current Rating
Political and Governance	☐ Substantial	☐ Substantial	☐ Substantial
Macroeconomic	☐ Substantial	☐ Moderate	☐ Moderate
Sector Strategies and Policies	☐ Substantial	☐ Substantial	☐ Substantial
Technical Design of Project or Program	☐ Substantial	☐ Low	☐ Low
Institutional Capacity for Implementation and Sustainability	☐ Substantial	☐ Substantial	☐ Substantial



Fiduciary	□ Substantial	□ High	□ High
Environment and Social	□ Substantial	□ Substantial	□ Substantial
Stakeholders	□ Moderate	□ Moderate	□ Moderate
Other	--	--	--
Overall	□ Substantial	□ High	□ High

Results

PDO Indicators by Objectives / Outcomes

Emergency COVID-19 Response				
▶ Diagnosed cases treated per approved protocol (Percentage, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	93.00	99.60	90.00
Date	27-Apr-2020	12-Apr-2021	16-Nov-2021	30-Jun-2024
▶ Total population vaccinated (Percentage, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	23.00	50.00
Date	16-Apr-2021	16-Apr-2021	16-Nov-2021	30-Jun-2024
□ Total female population vaccinated (Percentage, Custom Supplement)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	27.00	50.00
□ Total male population vaccinated (Percentage, Custom Supplement)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	18.00	50.00
▶ COVID-19 PCR tests processed within two days (Percentage, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	15.00	15.00	100.00	70.00
Date	16-Apr-2021	16-Apr-2021	16-Nov-2021	30-Jun-2024



Intermediate Results Indicators by Components

Emergency COVID-19 Response				
▶ Grievances addressed on time (as specified in the Stakeholder Engagement Plan) (Percentage, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	100.00	100.00	100.00
Date	01-Dec-2020	12-Apr-2021	16-Nov-2021	30-Jun-2024
▶ Doses of eligible COVID-19 vaccines procured (Number, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	151,000.00	800,000.00
Date	19-Apr-2021	19-Apr-2021	19-Apr-2021	30-Jun-2024
▶ Health staff trained in COVID-19 vaccination deployment per MOH-approved protocols (Number, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	270.00	400.00
Date	19-Apr-2021	19-Apr-2021	16-Nov-2021	30-Jun-2024
□ Female health staff trained in COVID-19 vaccination deployment per MOH-approved protocols (Number, Custom Breakdown)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	211.00	300.00
Date	19-Apr-2021	19-Apr-2021	16-Nov-2021	30-Jun-2024
□ Male health staff trained in COVID-19 vaccination deployment per MOH-approved protocols (Number, Custom Breakdown)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	59.00	100.00
Date	19-Apr-2021	19-Apr-2021	16-Nov-2021	30-Jun-2024
▶ A patient feedback mechanism for COVID-19 vaccinations is in place and functional (Yes/No, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	No	No	No	Yes



Date	19-Apr-2021	19-Apr-2021	16-Nov-2021	30-Jun-2024
► COVID-19 related information and education sessions targeting women (Number, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	53.00	500.00
Date	19-Apr-2021	19-Apr-2021	16-Nov-2021	30-Jun-2024
► Serious AEFI after COVID-19 vaccination investigated (Percentage, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	92.00	95.00
Date	19-Apr-2021	19-Apr-2021	16-Nov-2021	30-Jun-2024
► Intensive Care Units refurbished (Number, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	1.00	1.00	1.00	3.00
Date	19-Apr-2021	19-Apr-2021	16-Nov-2021	30-Jun-2024
► National Reference Laboratory is expanded, equipped and functional (Yes/No, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	No	No	No	Yes
Date	19-Apr-2021	19-Apr-2021	16-Nov-2021	30-Jun-2024
► Health staff trained in COVID-19 case management per MOH-approved protocols (Number, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	0.00	85.00
Date	19-Apr-2021	19-Apr-2021	16-Nov-2021	30-Jun-2024
► Oxygen plants established (Number, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	0.00	2.00
Date	19-Apr-2021	19-Apr-2021	16-Nov-2021	30-Jun-2024



Performance-Based Conditions

Data on Financial Performance


Disbursements (by loan)

Project	Loan/Credit/TF	Status	Currency	Original	Revised	Cancelled	Disbursed	Undisbursed	% Disbursed
P173939	IDA-66770	Effective	USD	7.50	7.50	0.00	6.72	0.78	90%
P173939	IDA-69300	Effective	USD	22.00	22.00	0.00	8.45	13.16	39%
P173939	TF-B5779	Effective	USD	3.50	3.50	0.00	0.92	2.58	26%

Key Dates (by loan)

Project	Loan/Credit/TF	Status	Approval Date	Signing Date	Effectiveness Date	Orig. Closing Date	Rev. Closing Date
P173939	IDA-66770	Effective	09-May-2020	12-May-2020	27-May-2020	30-Jun-2022	30-Jun-2022
P173939	IDA-69300	Effective	01-Jun-2021	11-Jun-2021	30-Jun-2021	30-Jun-2024	30-Jun-2024
P173939	TF-B5779	Effective	02-Jun-2021	11-Jun-2021	30-Jun-2021	30-Jun-2024	30-Jun-2024

Cumulative Disbursements





PBC Disbursement

PBC ID	PBC Type	Description	Coc	PBC Amount	Achievement Status	Disbursed amount in Coc	Disbursement % for PBC
--------	----------	-------------	-----	------------	--------------------	-------------------------	------------------------

Restructuring History

There has been no restructuring to date.

Related Project(s)

P176307-AF Lesotho COVID-19 Emergency Preparedness and Response Project
